SymBio Pharmaceuticals Limited (TYO:4582)
Japan · Delayed Price · Currency is JPY 87.00
0.00 (0.00%)
Feb 13, 2026, 3:30 PM JST
SymBio Pharmaceuticals Company Description
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally.
It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; and C-1101, an antiviral drug BCV injectable and oral formulations against double-stranded DNA viruses.
The company was incorporated in 2005 and is based in Minato, Japan.
SymBio Pharmaceuticals Limited
| Country | Japan |
| Founded | 2005 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Fuminori Yoshida |
Contact Details
Address: Toranomon Towers Office Minato, 105-0001 Japan | |
| Phone | 81 3 5472 1125 |
| Website | symbiopharma.com |
Stock Details
| Ticker Symbol | 4582 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3383050006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Fuminori Yoshida | Chief Executive Officer |
| Takeo Okuno | Chief Financial Officer |